American Portfolios Advisors Bio N Tech Se Transaction History

American Portfolios Advisors

  • $2.36 Trillion
  • Q3 2022

A detailed history of American Portfolios Advisors transactions in Bio N Tech Se stock. As of the latest transaction made, American Portfolios Advisors holds 174 shares of BNTX stock, worth $13,716. This represents 0.0% of its overall portfolio holdings.

Number of Shares
174
Holding current value
$13,716
% of portfolio
0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023
BUY
$127.65 - $183.11 $22,211 - $31,861
174 New
174 $23.5 Million
Q1 2022

Mar 21, 2023
BUY
$126.25 - $231.85 $378 - $695
3 Added 1.72%
177 $30.2 Million
Q4 2021

Mar 21, 2023
BUY
$216.64 - $362.52 $75,390 - $126,156
348 Added 200.0%
522 $135 Million
Q3 2021

Mar 22, 2023
BUY
$205.93 - $447.23 $886,734 - $1.93 Million
4,306 Added 2474.71%
4,480 $1.22 Billion
Q2 2021

Mar 22, 2023
BUY
$113.32 - $241.49 $587,450 - $1.25 Million
5,184 Added 2979.31%
5,358 $1.2 Billion
Q1 2021

Mar 22, 2023
BUY
$85.73 - $119.5 $410,732 - $572,524
4,791 Added 2753.45%
4,965 $542 Million
Q4 2020

Mar 22, 2023
BUY
$72.71 - $129.54 $947,556 - $1.69 Million
13,032 Added 7489.66%
13,206 $1.08 Billion
Q3 2020

Mar 22, 2023
BUY
$57.81 - $104.17 $715,340 - $1.29 Million
12,374 Added 7111.49%
12,548 $869 Million
Q2 2020

Mar 24, 2023
BUY
$38.58 - $66.74 $19,444 - $33,636
504 Added 4.09%
12,818 $855 Million
Q1 2020

Mar 24, 2023
BUY
$28.55 - $92.0 $346,597 - $1.12 Million
12,140 Added 6977.01%
12,314 $719 Million

Others Institutions Holding BNTX

# of Institutions
326
Shares Held
40.4M
Call Options Held
1.31M
Put Options Held
1.37M
View Full List

About BioNTech SE

BNTX Quotes by TradingView
  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $19.1B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email